Peptides · Peptide comparison
Dihexa vs Noopept (Omberacetam)
Angiotensin IV-derived oligopeptide that potentiates hepatocyte growth factor to drive synaptogenesis and cognitive enhancement with extraordinary potency
Ultra-potent dipeptide nootropic and prodrug of cycloprolylglycine that enhances cognition through BDNF/NGF upregulation, AMPA receptor modulation, and multicomponent neuroprotection at doses 1000 times lower than piracetam
- Cognitive
- Cognitive
At a glance
Quick comparison
Efficacy
Benefit ratings
Cognitive
Healing & Recovery
Anti-Aging
Memory & Learning
Brain Protection
Mental Clarity
Technical data
Compound specifications
Dihexa
- Molecular formula
- C27H44N4O5
- Molecular weight
- 504.7 g/mol
- Half-life
- ~12 days (following IV administration in rats)
- Bioavailability
- Orally active and blood-brain barrier permeable — specific oral bioavailability percentage not published
- CAS number
- 1401708-83-5
Noopept (Omberacetam)
- Molecular formula
- C17H22N2O4
- Molecular weight
- 318.4 g/mol
- Half-life
- Short plasma half-life (minutes); rapidly converted to active metabolite cycloprolylglycine which has a longer pharmacological duration; effects persist for hours after dosing
- Bioavailability
- Orally bioavailable with BBB penetration; metabolized to active cycloprolylglycine; approximately 1000-fold more potent than parent compound piracetam
- CAS number
- 157115-85-0
Protocols
Dosing compared
Dihexa
Oral
- 5–8 mgOnce daily · 2–4 weeksLower starting amount reported in practice. Dihexa has no human clinical trials, so all amounts come from animal research and community use [2][4].
- 8–20 mgOnce daily · 4–6 weeksCommonly reported daily range in practice for cognitive support [2][4].
- 20–45 mgOnce daily · 4–6 weeks, then reassessUpper end of amounts reported in practice. No long-term human safety data exists, so this should be approached with caution [2][4].
Sublingual
- 5–15 mgOnce daily · 4–6 weeksHeld under the tongue as an alternative to swallowing; amounts reported in practice are similar to oral use [4].
Topical
- 5–15 mg in DMSO carrierOnce daily · 4–6 weeksApplied to the skin in a DMSO solution to help absorption; used in practice as a non-oral option [4].
Noopept (Omberacetam)
Oral
- 10 mg twice daily (20 mg/day)Twice daily (morning and afternoon) · 56 days (8 weeks) per clinical studyDose used in a controlled human study of mild cognitive impairment, improving cognition with good tolerability [6].
Applications
Best suited for
Dihexa
- Age-Related Cognitive Decline
- Dihexa directly addresses the synaptic loss that underlies age-related cognitive decline by building new functional synaptic connections in the hippocampus. Animal studies demonstrate restored spatial learning in aged rats, [6] making it a compelling candidate for combating memory loss associated with aging.
- Neuroplasticity Enhancement
- Unlike nootropics that work through neurotransmitter modulation, dihexa drives physical neuroplasticity — the formation of new dendritic spines and synapses. [6] This makes it ideal for individuals looking to enhance their brain's capacity for learning and adaptation at a structural level.
- Neurodegenerative Disease Research
- Preclinical evidence in APP/PS1 Alzheimer's mice and scopolamine-induced amnesia models [4][6] positions dihexa as a leading research compound for neurodegenerative disease. It is patented for potential use in Alzheimer's and Parkinson's diseases, with ongoing interest from the research community.
- Advanced Nootropic Stacking
- Dihexa's unique mechanism (HGF/c-Met potentiation) is complementary to most other nootropic mechanisms, making it an excellent addition to advanced cognitive enhancement protocols when combined with choline donors, racetams, or adaptogens.
Noopept (Omberacetam)
- Cognitive enhancement for learning, memory formation, and information retrieval
- Noopept (Omberacetam) is particularly well-suited for individuals focused on cognitive enhancement for learning, memory formation, and information retrieval. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Neuroprotection against oxidative stress and age-related cognitive decline
- Noopept (Omberacetam) is particularly well-suited for individuals focused on neuroprotection against oxidative stress and age-related cognitive decline. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms
- Noopept (Omberacetam) is particularly well-suited for individuals focused on nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Support during periods of intense intellectual work or study
- Noopept (Omberacetam) is particularly well-suited for individuals focused on support during periods of intense intellectual work or study. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Dihexa
Common
- Headache
- Vivid dreams or altered sleep patterns
- Emotional sensitivity
- Mild fatigue during adjustment
Uncommon
- Gastrointestinal discomfort
Serious
- Theoretical oncogenic risk from c-Met activation
Noopept (Omberacetam)
Common
- Headache
- Irritability or restlessness
- Sleep disturbance
- Mild gastrointestinal discomfort
- Vivid dreams
Uncommon
- Blood pressure increase
Serious
- Allergic reaction
Research status
Safety & evidence
Dihexa
- Evidence level
- Preclinical only — animal and cell-culture studies; no human trials
- FDA status
- Research compound
- Safety overview
- Dihexa has demonstrated a favorable safety profile in published animal studies, with no reported tumorigenic effects or organ toxicity at cognitive-enhancing doses. However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist. [7] The primary theoretical safety concern is sustained activation of the HGF/c-Met proto-oncogenic pathway, which could theoretically promote tumor initiation or growth. [7] The extremely long half-life (~12 days) [6][7] raises additional concerns about compound accumulation with chronic daily dosing. Anecdotal reports from the nootropics community generally describe good tolerability at doses of 5-20 mg daily, with headaches and vivid dreams as the most commonly reported effects.
Contraindications
- Known or suspected malignancy — c-Met/HGF pathway activation may promote tumor growth
- Pregnancy and breastfeeding — no safety data available
- History of cancer, particularly HGF/c-Met-driven tumors (hepatocellular, gastric, lung)
- Severe hepatic impairment
Noopept (Omberacetam)
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Noopept demonstrates excellent safety in Russian clinical trials with LD50 >2000 mg/kg (oral, rats)—approximately 100 times higher than therapeutic doses. No serious adverse events reported in human studies up to 30 mg/day for 6-12 weeks. Mild side effects (headache, irritability) occur in <5% of users and resolve with dose reduction. No carcinogenicity, mutagenicity, or teratogenicity in preclinical testing; minimal drug interactions due to lack of hepatic CYP450 metabolism.
Contraindications
- Known hypersensitivity to Noopept, piracetam, or other racetam-class compounds
- Pregnancy and breastfeeding — insufficient safety data
- Severe hepatic impairment — Noopept undergoes hepatic metabolism
- Severe renal impairment — metabolites are renally excreted
- Lactose intolerance (some tablet formulations contain lactose as excipient)
Decision guide
Which is right for you?
Dihexa
Choose Dihexa if…
- Cognitive enhancement and memory consolidation in age-related decline
- Supporting neuroplasticity and new synaptic connection formation
- Research into neurodegenerative disease therapeutics (Alzheimer's, Parkinson's)
- Nootropic stacking for individuals seeking enhanced learning capacity
Noopept (Omberacetam)
Choose Noopept (Omberacetam) if…
- Cognitive enhancement for learning, memory formation, and information retrieval
- Neuroprotection against oxidative stress and age-related cognitive decline
- Nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms
- Support during periods of intense intellectual work or study